| Literature DB >> 26705257 |
Juan Yang1,2, Xiaofan Xiong1,2, Siyuan Liu1,2, Jiang Zhu3, Mai Luo1,2, Liying Liu1,2, Lingyu Zhao1,2, Yannan Qin1,2, Tusheng Song1,2, Chen Huang1,2.
Abstract
This study aimed to identify novel serum peptides biomarkers for female breast cancer (BC) patients. We analyzed the serum proteomic profiling of 247 serum samples from 96 BC patients, 48 additional paired pre- and postoperative BC patients, 39 fibroadenoma patients as benign disease controls, and 64 healthy controls, using magnetic-bead-based separation followed by MALDI-TOF MS. ClinProTools software identified 78 m/z peaks that differed among all analyzed groups, ten peaks were significantly different (P < 0.0001), with Peaks 1-6 upregulated and Peaks 7-10 downregulated in BC. Moreover, three peaks of ten (Peak 1, m/z: 2660.11; Peak 2, m/z: 1061.09; Peak 10, m/z: 1041.25) showed a tendency to return to healthy control values after surgery. And these three peptide biomarkers were identified as FGA605-629, ITIH4 347-356, and APOA2 43-52. Methods used in this study could generate serum peptidome profiles of BC, and provide a new approach to identify potential biomarkers for diagnosis as well as prognosis of this malignancy.Entities:
Keywords: Breast cancer; Cell biology; Fibroadenoma; MALDI-TOF MS; Serum biomarker
Mesh:
Substances:
Year: 2016 PMID: 26705257 DOI: 10.1002/pmic.201500321
Source DB: PubMed Journal: Proteomics ISSN: 1615-9853 Impact factor: 3.984